Meeting
2018 ASCO Annual Meeting
Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.
Authors
Jennifer Rachel Eads
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
Jennifer Rachel Eads , Smitha S. Krishnamurthi , Joel N. Saltzman , David Lawrence Bajor , Shaveta Vinayak , Jill Barnholtz-Sloan , Neal J. Meropol , Sanford D. Markowitz , Zhenghe Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02861300
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2562)
DOI
10.1200/JCO.2018.36.15_suppl.2562
Abstract #
2562
Poster Bd #
388
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.
First Author: Mirella Nardo
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2019 ASCO Annual Meeting
A phase I study evaluating COM701 in patients with advanced solid tumors.
First Author: Drew W. Rasco